# Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct02607865` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02607865](<https://clinicaltrials.gov/study/NCT02607865>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02607865

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1864 participants.

## Technical summary

Registry record NCT02607865. Randomized; double masking; primary purpose treatment. Start 2016-02-15 (actual); primary completion 2017-02-14 (actual). Results posted on 2020-02-27.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1864 participants (enrolled count; ClinicalTrials.gov record NCT02607865, source copy `cardio:ctgov-nct02607865-2022-07-20`, retrieved 2026-10-26)
- Started: 2016-02-15 (actual) (ClinicalTrials.gov record NCT02607865, source copy `cardio:ctgov-nct02607865-2022-07-20`, retrieved 2026-10-26)
- Primary completion: 2017-02-14 (actual) (ClinicalTrials.gov record NCT02607865, source copy `cardio:ctgov-nct02607865-2022-07-20`, retrieved 2026-10-26)
- Completion: 2018-03-28 (actual) (ClinicalTrials.gov record NCT02607865, source copy `cardio:ctgov-nct02607865-2022-07-20`, retrieved 2026-10-26)
- Results first posted: 2020-02-27 (ClinicalTrials.gov record NCT02607865, source copy `cardio:ctgov-nct02607865-2022-07-20`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; France; Germany; India; Israel; Japan; Mexico; Romania; Russia; South Africa; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02607865, source copy `cardio:ctgov-nct02607865-2022-07-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02607865-2022-07-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
- Acronym: PIONEER 3
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): sitagliptin
- Intervention (Drug): placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial (`cardio:pubmed-30903796`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials (`cardio:pubmed-34472698`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a6ec3fee5c2d28b0b4c0e666e37754ee500e38f9cb3660480885e2514b468878
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
